Teplizumab, sold under the brand name Tzield, is a humanized anti-CD3 monoclonal antibody that is the first approved treatment indicated to delay the onset of stage 3 type 1 diabetes in people with stage 2 type 1 diabetes. From Wikipedia
Case-by-case NHS teplizumab access paves the way for licensing talks with national screening initiatives preparing to identify at-risk adults early.
